Exosomes isolated from IMMUNEPOTENT CRP, a hemoderivative, to accelerate diabetic wound healing

Area of Science:

• Biomedical Science
• Wound Healing Research
• Diabetic Complications

Background:

• Diabetic foot ulcers pose a significant risk of amputation, necessitating novel therapeutic strategies.
• Understanding the role of IMMUNEPOTENT CRP (ICRP) and its components in wound repair is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the therapeutic potential of IMMUNEPOTENT CRP (ICRP) and its fractions (pellets, supernatants, exosomes, exosome-insulin) in accelerating diabetic wound healing.
• To elucidate the underlying mechanisms, including cellular viability, scratch healing, collagen production, and inflammatory responses, mediated by ICRP components.

Main Methods:

• ICRP components were isolated and characterized, with exosomes loaded with insulin.
• In vitro studies assessed cell viability and scratch healing in NIH-3T3, HUVEC, and HACAT cell lines.
• In vivo studies involved topical application of treatments to diabetic mouse models with induced wounds, followed by monitoring wound closure, cytokine levels, and histological analysis.

Main Results:

• ICRP pellets and exosomes enhanced cellular viability in vitro.
• Exosomes and exosome-insulin formulations accelerated scratch healing in vitro, with exosome-insulin demonstrating sustained insulin release.
• In vivo, all ICRP treatments accelerated wound closure, with pellets, exosomes, and exosome-insulin showing superior efficacy.
• ICRP treatment promoted collagen expression, and phosphorylation of AKT pathway components (p-AKT, p-FOXO) was observed in healing tissues.
• All treatments effectively downregulated inflammatory cytokines.

Conclusions:

• IMMUNEPOTENT CRP components, especially exosomes and exosome-insulin, are promising therapeutic agents for accelerating diabetic wound healing.
• These components promote cellular proliferation, collagen synthesis, and modulate inflammation through the AKT signaling pathway.
• Exosome-based delivery systems, particularly for insulin, offer a sustained release mechanism for enhanced therapeutic outcomes.